Thymalfasin: an immune system enhancer for the treatment of liver disease
- 19 November 2004
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (S6) , S69-72
- https://doi.org/10.1111/j.1440-1746.2004.03635.x
Abstract
Abstract Thymalfasin (thymosin‐alpha 1) is an immunomodulating agent able to enhance the Th1 immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer. The basis for effectiveness in these conditions is primarily through modulation of immunological responsiveness, as thymalfasin has been shown to have beneficial effects on numerous immune system parameters and to increase T‐cell differentiation and maturation.Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals. In addition, thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects.© 2004 Blackwell Publishing Asia Pty LtdThis publication has 11 references indexed in Scilit:
- Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinomaInternational Immunopharmacology, 2003
- In vitro effect of thymosin‐α1 and interferon‐α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis CJournal of Viral Hepatitis, 2001
- Pathogenesis of Experimental Neonatal Woodchuck Hepatitis Virus Infection: Chronicity As An Outcome of Infection Is Associated With A Diminished Acute Hepatitis That Is Temporally Deficient for the Expression of Interferon Gamma and Tumor Necrosis Factor–Alpha Messenger RnasHepatology, 2001
- Decrease of Cd56+T Cells and Natural Killer Cells in Cirrhotic Livers With Hepatitis C May Be Involved in Their Susceptibility to Hepatocellular CarcinomaHepatology, 2000
- Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin α-1International Journal of Immunopharmacology, 2000
- Thymosin-α1 regulates MHC class I expression in FRTL-5 cells at transcriptional levelEuropean Journal of Immunology, 2000
- Efficacy of repeated cycles of chemo-immunotherapy with Thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil deliveryCancer Immunology, Immunotherapy, 1999
- Thymosin- α 1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture modelInternational Journal of Immunopharmacology, 1999
- Immunotherapy with natural interleukins and/or thymosin α1 potently augments T-lymphocyte responses of hydrocortisone-treated aged miceInternational Journal of Immunopharmacology, 1995
- A Preliminary Report of a Controlled Study of Thymosin Alpha-1 in the Woodchuck Model of Hepadnavirus InfectionPublished by Springer Nature ,1992